Eyepoint Pharmaceuticals (EYPT) Insider Trading & Ownership $11.60 -0.24 (-2.03%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$11.78 +0.18 (+1.52%) As of 08/28/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.46%Number OfInsiders Buying(Last 3 Years)7Amount OfInsider Buying(Last 3 Years)$89.52MNumber OfInsiders Selling(Last 3 Years)10Amount OfInsider Selling(Last 3 Years)$49.56M Get EYPT Insider Trade Alerts Want to know when executives and insiders are buying or selling Eyepoint Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EYPT Insider Buying and Selling by Quarter Eyepoint Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/20/2024Wendy F DiciccoDirectorBuy2,567$7.79$19,996.93 7/12/2024David R GuyerDirectorSell11,625$10.06$116,947.50 5/14/2024David R GuyerDirectorSell11,625$12.65$147,056.25 5/6/2024Cormorant Asset Management, LpMajor ShareholderBuy850,000$11.86$10,081,000.00 4/18/2024Cormorant Asset Management, LpMajor ShareholderBuy581,765$18.03$10,489,222.95 2/2/2024David Scott JonesSVPSell209$28.49$5,954.41 1/26/2024Dario A PaggiarinoInsiderSell49,325$25.66$1,265,679.50 1/25/2024David Scott JonesSVPSell600$25.00$15,000.00 1/23/2024Dario A PaggiarinoInsiderSell5,135$25.00$128,375.00 1/23/2024David Scott JonesSVPSell900$25.00$22,500.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 1/11/2024Cormorant Asset Management, LpMajor ShareholderBuy750,000$19.75$14,812,500.00 1/11/2024Ye LiuDirectorSell1,910,500$19.45$37,159,225.00 1/9/2024Cormorant Asset Management, LpMajor ShareholderBuy105,000$21.32$2,238,600.00 1/8/2024Dario A PaggiarinoInsiderSell22,913$21.13$484,151.69 12/13/2023Dario A PaggiarinoInsiderSell1,458$20.00$29,160.00 12/8/2023Cormorant Asset Management, LpMajor ShareholderBuy588,235$17.00$9,999,995.00 12/6/2023Ye LiuDirectorSell266,242$18.41$4,901,515.22 12/4/2023Cormorant Asset Management, LpMajor ShareholderBuy1,919,057$21.82$41,873,823.74 12/4/2023Michael Craig PineInsiderSell45,000$22.00$990,000.00 9/1/2023Ew Healthcare Partners, L.P.Major ShareholderSell20,000$9.90$198,000.00 8/30/2023Ew Healthcare Partners, L.P.Major ShareholderSell60,976$10.92$665,857.92 8/28/2023Ew Healthcare Partners, L.P.Major ShareholderSell60,858$11.71$712,647.18 8/24/2023Ew Healthcare Partners, L.P.Major ShareholderSell139,280$14.62$2,036,273.60 8/22/2023Ew Healthcare Partners, L.P.Major ShareholderSell46,778$14.62$683,894.36 5/30/2023Ye LiuDirectorSell1$6.00$6.00 (Data available from 1/1/2013 forward) EYPT Insider Trading Activity - Frequently Asked Questions Who is on Eyepoint Pharmaceuticals' Insider Roster? The list of insiders at Eyepoint Pharmaceuticals includes Cormorant Asset Management, Lp, Dario A Paggiarino, David R Guyer, David Scott Jones, Ew Healthcare Partners, L.P., Michael Craig Pine, Wendy F Dicicco, and Ye Liu. Learn more on insiders at EYPT. What percentage of Eyepoint Pharmaceuticals stock is owned by insiders? 4.46% of Eyepoint Pharmaceuticals stock is owned by insiders. Learn more on EYPT's insider holdings. Which Eyepoint Pharmaceuticals insiders have been buying company stock? The following insiders have purchased EYPT shares in the last 24 months: Cormorant Asset Management, Lp ($89,495,141.69), and Wendy F Dicicco ($19,996.93). How much insider buying is happening at Eyepoint Pharmaceuticals? Insiders have purchased a total of 4,796,624 EYPT shares in the last 24 months for a total of $89,515,138.62 bought. Which Eyepoint Pharmaceuticals insiders have been selling company stock? The following insiders have sold EYPT shares in the last 24 months: Dario A Paggiarino ($1,907,366.19), David R Guyer ($264,003.75), David Scott Jones ($43,454.41), Ew Healthcare Partners, L.P. ($863,857.92), Michael Craig Pine ($990,000.00), and Ye Liu ($42,060,740.22). How much insider selling is happening at Eyepoint Pharmaceuticals? Insiders have sold a total of 2,406,508 Eyepoint Pharmaceuticals shares in the last 24 months for a total of $46,129,422.49 sold. Eyepoint Pharmaceuticals Key ExecutivesDr. Jay S. Duker M.D. (Age 65)President, CEO & Director Compensation: $848.5kDr. John B. Landis M.S. (Age 71)Ph.D., Interim Head of R&D and Director Compensation: $63.75kMr. Michael Pine (Age 47)Chief Business Officer Compensation: $764.85kMr. George O. Elston (Age 59)Executive VP & CFO Compensation: $743.86kMr. Michael J. MaciocioSenior Vice President of Manufacturing & OperationsMr. Ron I. Honig Esq.Chief Legal Officer & Company SecretaryMs. Jennifer LeonardChief People Officer & Senior VP of ITMr. David Scott Jones (Age 56)Senior VP & Chief Commercial Officer Compensation: $672.08kMs. Isabelle LefebvreChief Regulatory OfficerDr. Marcia Sellos-Moura Ph.D.Senior Vice President of Program Leadership More Insider Trading Tools from MarketBeat Related Companies TXG Insider Trades TRNS Insider Trades ALNT Insider Trades AEHR Insider Trades CTKB Insider Trades LAB Insider Trades SENS Insider Trades FEIM Insider Trades MASS Insider Trades QSI Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:EYPT) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access